From: Histological evaluation of AMPK signalling in primary breast cancer
Parameter | Cohort 1 [n (%)] | Cohort 2 [n (%)] | P |
---|---|---|---|
N | 117 | 237 | Â |
Menopausal status at diagnosis | Â | Â | Â |
   Pre- and peri-menopausal | 62 (53) | 56 (24) | < 0.001* |
   Post-menopausal | 55 (47) | 181 (76) |  |
Age (years) | Â | Â | Â |
   Median (range) | 51 (34-76) | 62 (28-89) | < 0.001~ |
Tumour size (cm) | Â | Â | Â |
   ≤ 2 | 61 (57) | 88 (37) | < 0.001* |
   > 2 | 46 (43) | 148 (63) |  |
Number of positive lymph nodes | Â | Â | Â |
   0 | 48 (41) | 127 (54) | 0.032*†0.540*‡ |
   1-3 | 48 (41) | 74 (31) |  |
   > 3 | 21 (18) | 36 (15) |  |
Histological grade | Â | Â | Â |
   1 | 12 (10) | 34 (14) | 0.399*†0.425*‡ |
   2 | 43 (38) | 91 (39) |  |
   3 | 59 (52) | 110 (47) |  |
Adjuvant therapy | Â | Â | Â |
   Endocrine therapy | 18 (16) | 59 (27) | N/A |
   Chemotherapy and/or Radiotherapy | 0 (0) | 54 (24) |  |
   Endocrine + Chemotherapy | 12 (10) | 10 (4) |  |
   Endocrine + Radiotherapy | 45 (38) | 70 (31) |  |
   Endocrine + Chemo + Radiotherapy | 42 (36) | 31 (14) |  |
Follow up (months) | Â | Â | Â |
   Median (range) | 73 (9-122) | 60 (1-120) | < 0.001~ |